Research &amp; Development

Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK),...

Time is of the essence for millions living with ‘neglected’ lung disease

Your Time campaign calls for earlier action in COPDWHO expects COPD to be the third leading cause of death worldwide...

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

Collaborations aim to speed research and development approaches in Crohn’s disease and ulcerative colitisIcahn School of Medicine, Massachusetts General Hospital,...

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®

Studies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD...

AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers

AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive...

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of...

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg...

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan